Gerald Simonneau

Summary

Country: France

Publications

  1. ncbi request reprint A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer
    G Simonneau
    Department of Pulmonary and Critical Medicine, Antoine Beclere University Hospital, Clamart, France
    J Thromb Haemost 4:1693-700. 2006
  2. ncbi request reprint Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Gerald Simonneau
    National Reference Center for Pulmonary Hypertension South Paris University, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France
    Eur Respir J 40:874-80. 2012
  3. doi request reprint A hemodynamic study of pulmonary hypertension in sickle cell disease
    Florence Parent
    Universite Paris Sud, Kremlin Bicetre, Hopital Antoine Beclere, Clamart, France
    N Engl J Med 365:44-53. 2011
  4. doi request reprint Updated clinical classification of pulmonary hypertension
    Gerald Simonneau
    Centre National de Référence des Maladies Vasculaires Pulmonaires, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Am Coll Cardiol 54:S43-54. 2009
  5. ncbi request reprint [A new clinical classification of pulmonary hypertension]
    Gerald Simonneau
    Universite Paris Sud 11, UPRES EA 2705, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Pneumologie et Réanimation respiratoire, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux 92141 Clermont cedex, France
    Bull Acad Natl Med 193:1897-909. 2009
  6. doi request reprint Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
    David Launay
    Universite Paris Sud, Faculte de Medecine, Kremlin Bice tre, France
    Rheumatology (Oxford) 49:490-500. 2010
  7. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
  8. doi request reprint Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
  9. ncbi request reprint Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    N Engl J Med 351:1425-36. 2004
  10. doi request reprint Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010

Detail Information

Publications136 found, 100 shown here

  1. ncbi request reprint A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer
    G Simonneau
    Department of Pulmonary and Critical Medicine, Antoine Beclere University Hospital, Clamart, France
    J Thromb Haemost 4:1693-700. 2006
    ..The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable...
  2. ncbi request reprint Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Gerald Simonneau
    National Reference Center for Pulmonary Hypertension South Paris University, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France
    Eur Respir J 40:874-80. 2012
    ..Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect. Our results encourage the further investigation of selexipag for the treatment of PAH...
  3. doi request reprint A hemodynamic study of pulmonary hypertension in sickle cell disease
    Florence Parent
    Universite Paris Sud, Kremlin Bicetre, Hopital Antoine Beclere, Clamart, France
    N Engl J Med 365:44-53. 2011
    ..The prevalence and characteristics of pulmonary hypertension in adults with sickle cell disease have not been clearly established...
  4. doi request reprint Updated clinical classification of pulmonary hypertension
    Gerald Simonneau
    Centre National de Référence des Maladies Vasculaires Pulmonaires, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Am Coll Cardiol 54:S43-54. 2009
    ..Finally, it was decided to place pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to Group 1 (now called Group 1'). Thus, Group 1 of PAH is now more homogeneous...
  5. ncbi request reprint [A new clinical classification of pulmonary hypertension]
    Gerald Simonneau
    Universite Paris Sud 11, UPRES EA 2705, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Pneumologie et Réanimation respiratoire, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux 92141 Clermont cedex, France
    Bull Acad Natl Med 193:1897-909. 2009
    ....
  6. doi request reprint Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
    David Launay
    Universite Paris Sud, Faculte de Medecine, Kremlin Bice tre, France
    Rheumatology (Oxford) 49:490-500. 2010
    ..We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of prostanoids or sildenafil...
  7. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
    ..A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations...
  8. doi request reprint Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
    ..Because they are generally excluded from randomized controlled trials, little is known about these patients...
  9. ncbi request reprint Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    N Engl J Med 351:1425-36. 2004
  10. doi request reprint Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010
    ..We conducted a study to characterize mortality in a multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension in the modern management era...
  11. ncbi request reprint [Pulmonary arterial hypertension]
    Xavier Jais
    Centre de référence de l hypertension pulmonaire sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 92141 Clamart Cedex, France
    Rev Prat 58:1997-2010. 2008
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  12. doi request reprint Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation
    Barbara Girerd
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, 92140 Clamart, France
    Am J Respir Crit Care Med 181:851-61. 2010
    ..Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH)...
  13. ncbi request reprint Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension
    Hilario Nunes
    UPRES 2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 167:1433-9. 2003
    ..These results suggest that patients with severe human immunodeficiency virus-associated PAH should be considered for long-term epoprostenol infusion in association with CART...
  14. doi request reprint HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
    Bruno Degano
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    AIDS 24:67-75. 2010
    ....
  15. doi request reprint Pulmonary veno-occlusive disease: recent progress and current challenges
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U999, Centre National de Référence de l Hypertension Pulmonaire Sévère, 92140 Clamart, France
    Respir Med 104:S23-32. 2010
    ..Unfortunately, the long term effects of these agents are variable and lung transplantation remains the treatment of choice...
  16. ncbi request reprint Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP Université Paris Sud, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Heart J 27:589-95. 2006
    ..Data on long-term efficacy of bosentan in unselected idiopathic pulmonary arterial hypertension (IPAH) patients are lacking. We aimed to describe the long-term outcome of consecutive IPAH patients treated first-line with bosentan...
  17. doi request reprint Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, F 94276, France
    Expert Opin Pharmacother 12:1585-96. 2011
    ..Therapeutic strategies that modulate the activity of endothelin are, therefore, of interest to improve the functional status of patients with PAH...
  18. doi request reprint Portopulmonary hypertension: survival and prognostic factors
    Jerome Le Pavec
    Universite Paris Sud 11, UPRES 2705, Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 178:637-43. 2008
    ..Survival results in PoPH are contrasting, and prognostic factors need to be identified...
  19. ncbi request reprint [Pulmonary hypertension associated with systemic sclerosis]
    Olivier Sanchez
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Ann Med Interne (Paris) 153:250-9. 2002
    ..Novel therapies including oral, sub-cutaneous or inhaled stable prostacyclin analogues and endothelin receptor antagonists are currently evaluated in large placebo-controlled trials...
  20. doi request reprint Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial
    Xavier Jais
    Antoine Beclere Hospital, Clamart, France
    J Am Coll Cardiol 52:2127-34. 2008
    ..Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH)...
  21. ncbi request reprint Chemokine RANTES in severe pulmonary arterial hypertension
    Peter Dorfmuller
    Center for Pulmonary Vascular Diseases, UPRES EA 2705, France
    Am J Respir Crit Care Med 165:534-9. 2002
    ..These results support the concept that inflammatory mechanisms play a role in the natural history of pulmonary arterial hypertension...
  22. doi request reprint Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
    David Montani
    Universite Paris Sud, Orsay, France
    Adv Ther 26:813-25. 2009
    ..Due to their clinical effectiveness, tolerance profile, and their oral administration, sildenafil and tadalafil are two of the recommended first-line therapies for PAH patients in World Health Organization functional classes II or III...
  23. doi request reprint Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicêtre F 94276, France
    Respir Med 104:S74-80. 2010
    ..This review details the rationale for the different combination strategies and examines the clinical evidence in favour of some of the approaches that have been evaluated...
  24. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  25. ncbi request reprint Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension
    Olivier Sanchez
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Chest 130:182-9. 2006
    ..Immunosuppressive therapy should be better evaluated in this setting.Study design: Monocentric retrospective study...
  26. ncbi request reprint Primary pulmonary hypertension: Current therapy
    Olivier Sitbon
    Service de Pneumologie et Reanimation Respiratoire, Pulmonary Vascular Center, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Prog Cardiovasc Dis 45:115-28. 2002
    ..In such patients with severe pulmonary hypertension refractory to medical therapy, atrioseptostomy and lung transplantation can be indicated...
  27. ncbi request reprint Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension
    Ségolène Cabrol
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Heart Lung Transplant 26:357-62. 2007
    ..Vascular remodeling lesions can be found in lungs of patients with CTEPH. Little is known about epoprostenol therapy in inoperable distal CTEPH patients...
  28. ncbi request reprint Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    Olivier Sitbon
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, AP HP, Universite Paris Sud, Clamart, France
    Circulation 111:3105-11. 2005
    ..Characteristics of patients with idiopathic pulmonary arterial hypertension (IPAH) who benefit from long-term calcium channel blockers (CCB) are unknown...
  29. doi request reprint Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study
    Kristina Kemp
    Universite Paris Sud 11, Faculte de Medecine, Le Kremlin Bicetre, Clamart, France
    J Heart Lung Transplant 31:150-8. 2012
    ..Recent guidelines have proposed first-line combination therapy as a potential strategy for the treatment of functional class IV pulmonary arterial hypertension (PAH)...
  30. ncbi request reprint [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]
    Olivier Sitbon
    Centre de référence national de l HTAP, Service de Pneumologie, UPRES EA2705, Hopital Antoine Beclere, AP HP, Université Paris XI Sud, 92141 Clamart Cedex, France
    Rev Prat 58:2011-8. 2008
    ..However, their prognosis differs greatly: it is poor in scleroderma, and much better in congenital heart diseases...
  31. doi request reprint Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases
    Xavier Jais
    Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Arthritis Rheum 58:521-31. 2008
    ..To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD)...
  32. doi request reprint [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]
    David Montani
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Presse Med 39:134-43. 2010
    ..In patients with the most severe disease, the prudent use of continuous intravenous epoprostenol, can serve as bridge-therapy while awaiting a lung transplant...
  33. doi request reprint Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology
    David Montani
    Universite Paris Sud 11, UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Paris, France
    Medicine (Baltimore) 87:220-33. 2008
    ..Clinical outcomes of PVOD patients were worse than those of PAH patients...
  34. doi request reprint Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival
    Marc Humbert
    Universite Paris Sud, Le Kremlin Bicetre, France AP HP Hôpital Antoine Béclère, Clamart, France
    Arthritis Rheum 63:3522-30. 2011
    ..However, little is known about the impact of detection programs on patients with SSc-PAH. This study was undertaken to assess the clinical characteristics of patients with SSc-PAH at diagnosis and their long-term outcomes...
  35. ncbi request reprint Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
    Olivier Sitbon
    Service de Pneumologie Réanimation Respiratoire, Hopital Antoine Beclere, 157, Avenue de la Porte Trivaux, F 92141 Clamart Cedex, France
    Chest 124:247-54. 2003
    ..We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH)...
  36. doi request reprint Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation
    Benjamin Sztrymf
    Universite Paris Sud 11, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:1377-83. 2008
    ..Germline mutations in the gene encoding for bone morphogenetic protein receptor 2 (BMPR2) are a cause of pulmonary arterial hypertension (PAH)...
  37. ncbi request reprint An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation
    Xavier Jais
    UPRES EA 2705, Service de Pneumologie, Hopital Antoine Béclere AP HP, Universite Paris Sud, Clamart, France
    Hemoglobin 27:139-47. 2003
    ..This case ranks as one of the most severe examples ever recorded of the effect that splenectomy may have in DHS patients. Nonetheless, it represents the first case to receive a heart-lung transplant...
  38. doi request reprint Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
    Laurent Savale
    Faculte de Medecine, Universite Paris Sud 11, France
    Eur Respir J 41:96-103. 2013
    ..Haemodynamic improvements were particularly pronounced in patients with more severe cirrhosis. The safety profile of bosentan was consistent with previous studies...
  39. doi request reprint Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences
    David Montani
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Semin Respir Crit Care Med 30:411-20. 2009
    ..Lung transplantation remains the treatment of choice, but cautious use of specific PAH therapy can be helpful in select patients while awaiting this intervention...
  40. ncbi request reprint Pulmonary arterial hypertension in France: results from a national registry
    Marc Humbert
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 173:1023-30. 2006
    ..Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach...
  41. doi request reprint Therapeutic advances in pulmonary arterial hypertension
    K Boutet
    Universite Paris Sud 11, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Ther Adv Respir Dis 2:249-65. 2008
    ..Despite those important advances there is still no cure for PAH. Fortunately, research is ongoing and many drugs show promises...
  42. ncbi request reprint Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
    Olivier Sitbon
    Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 40:780-8. 2002
    ..We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion...
  43. ncbi request reprint Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
    Olivier Sitbon
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 170:1212-7. 2004
    ....
  44. doi request reprint Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension
    Denis Chemla
    Universite Paris Sud, Faculte de Medecine, EA4533, Le Kremlin Bicetre, France
    Chest 143:1343-50. 2013
    ..Our retrospective, high-fidelity pressure study tested the hypothesis that msePAP was proportional to mPAP, and looked at the implications for RVSW...
  45. doi request reprint Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension
    Frederic Perros
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Institut Paris Sud Cytokines, Hopital Antoine Beclere, Universite Paris Sud 11, UPRES EA 2705, Clamart, France
    Am J Respir Crit Care Med 178:81-8. 2008
    ....
  46. doi request reprint Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure
    Delphine Natali
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Chest 140:1066-8. 2011
    ..In this case report, we hypothesize that PTEN mutations may be a predisposing factor for the development of PAH, with anorexigen exposure as a potential trigger...
  47. doi request reprint Treatment of pulmonary arterial hypertension with targeted therapies
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicêtre F 94276, France
    Nat Rev Cardiol 8:526-38. 2011
    ..In this Review, we highlight the pharmacological agents currently available for the treatment of PAH and discuss potential novel strategies...
  48. ncbi request reprint The CX3C chemokine fractalkine in allergic asthma and rhinitis
    Anne Cécile Rimaniol
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Allergy Clin Immunol 112:1139-46. 2003
    ..Because of its dual activity, fractalkine plays a major role in the transendothelial and transepithelial migration of leukocytes during inflammation...
  49. ncbi request reprint Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
    Steeve Provencher
    Service de Pneumologie et Réanimation Hôpital Antoine Béclère, Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, AP HP Université Paris Sud, Clamart, France
    Expert Opin Pharmacother 6:1337-48. 2005
    ..In the present report, the pharmacology, clinical efficacy and safety profile of bosentan are summarised. The place of bosentan among the current therapies available for the treatment of PAH is also discussed...
  50. ncbi request reprint Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study
    Dominique Musset
    Service de Radiologie, Hôpital Universitaire Antoine Béclère, Clamart, France
    Lancet 360:1914-20. 2002
    ..The main aim was to assess the safety of withholding anticoagulant treatment in patients with low or intermediate clinical probability of PE and negative findings on spiral CT and ultrasonography...
  51. ncbi request reprint [Deep venous thrombosis and pulmonary embolism]
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA2705, Hopital Antoine Beclere, Universite Paris Sud, 92140 Clamart
    Rev Prat 52:555-64. 2002
  52. doi request reprint Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
    Andrei Seferian
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Eur Respir J 40:75-83. 2012
    ..Future recommendations should be amended according to these results suggesting that V'/Q' lung scanning is not useful in discriminating PVOD from idiopathic PAH...
  53. ncbi request reprint Idiopathic pulmonary hypertension: what did we learn from genes?
    Benjamin Sztrymf
    UPRES 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Sarcoidosis Vasc Diffuse Lung Dis 22:S91-100. 2005
    ..Nevertheless, PAH pathobiology remains unclear and genomic approaches may identify additional molecular determinants for this disorder...
  54. doi request reprint Pulmonary arterial hypertension and HIV infection
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France
    Semin Respir Crit Care Med 30:440-7. 2009
    ..Other PAH therapies, including prostacyclin analogs, type 5 phosphodiesterase inhibitors, and single endothelin receptor antagonists, have yet to be evaluated in PAH-HIV...
  55. ncbi request reprint Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era
    Olivier Sitbon
    Service de Pneumologie Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Am J Respir Crit Care Med 177:108-13. 2008
    ..The prevalence of HIV-associated pulmonary arterial hypertension (PAH) has not been evaluated since introduction of combined, highly active antiretroviral treatments...
  56. pmc Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension
    Peter Dorfmuller
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Respir Res 12:119. 2011
    ..The impact of OS on vascular remodeling in PH is still to be determined. We hypothesized, that augmented blood-flow could increase OS and might thereby contribute to DC/inflammatory cell-recruitment and smooth-muscle-cell-proliferation...
  57. ncbi request reprint Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Gastroenterology 130:120-6. 2006
    ..The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding...
  58. ncbi request reprint Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature
    David Launay
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    Medicine (Baltimore) 86:299-315. 2007
    ..In conclusion, this report underlines the rarity and severity of PAH in pSS patients. The best therapeutic regimen remains to be defined but should include standard PAH therapy and/or immunosuppressants...
  59. doi request reprint Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?
    Dermot S O'Callaghan
    Faculte de Medecine, Universite Paris Sud, 94276 Kremlin Bicêtre, France
    Presse Med 40:e65-78. 2011
    ..This review summarises the epidemiologic, clinico-pathologic and imaging characteristics of PVOD in the setting of CTD and discusses potential management approaches...
  60. doi request reprint Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure
    Benjamin Sztrymf
    Réanimation Médicale, Hopital Antoine Beclere, AP HP, Clamart, France
    Respiration 85:464-70. 2013
    ..Renal replacement therapy has been suggested as a therapeutic option in the setting of acute right ventricular failure in patients with severe precapillary pulmonary hypertension. However, there are few data supporting this strategy...
  61. doi request reprint [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 40:1S54-60. 2011
    ..Finally, clinical trials evaluating combinations of treatments have shown encouraging results...
  62. doi request reprint C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension
    David Montani
    University Paris Sud, Faculte de Medecine, Kremlin Bicetre, France
    Am J Respir Crit Care Med 184:116-23. 2011
    ..Because recent studies suggest that c-kit may be a target for innovative therapies in experimental pulmonary hypertension, we investigated the contribution of c-kit(+) cells in human idiopathic pulmonary arterial hypertension (IPAH)...
  63. ncbi request reprint Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Cardiovasc Pharmacol 49:1-5. 2007
    ..Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol...
  64. ncbi request reprint Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease
    Arnaud Resten
    Service de Radiologie, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, Clamart 92140, France
    AJR Am J Roentgenol 183:65-70. 2004
    ..The aim of our study was to evaluate this disease noninvasively using CT of the chest...
  65. doi request reprint Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Curr Opin Pulm Med 16:S21-6. 2010
    ..Treatment goals need to be carefully defined in order to correctly measure whether a treatment is successful and indicate when additional treatment is required...
  66. ncbi request reprint Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UP RES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud XI, Hopital Antoine Beclere, Clamart, France
    Chest 128:622S-628S. 2005
    ..Early detection and adequate clinical classification of the disease, better assessment of patients' prognosis, and improved therapeutic strategies are important challenges for clinicians in coming years...
  67. doi request reprint Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
    Marie Camille Chaumais
    Universite Paris Sud, Faculte de Pharmacie, Chatenay Malabry, France
    Expert Opin Drug Metab Toxicol 9:1193-205. 2013
    ..Sildenafil citrate is a potent, selective phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) and plays an important role in the management of the disease...
  68. doi request reprint Drug-induced pulmonary arterial hypertension: a recent outbreak
    David Montani
    Universite Paris Sud, Le Kremlin Bicetre, France
    Eur Respir Rev 22:244-50. 2013
    ..PAH remains a rare complication of these drugs, suggesting possible individual susceptibility, and further studies are needed to identify patients at risk of drug-induced PAH. ..
  69. ncbi request reprint Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  70. ncbi request reprint Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension
    David Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Université Paris Sud 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Chest 131:101-8. 2007
    ..Endothelin (ET)-1 has been shown to play a significant pathogenic role in PAH. ET-3 has not yet been investigated in PAH...
  71. ncbi request reprint Clinical classification of pulmonary hypertension
    Gerald Simonneau
    Department of Pulmonary and Critical Medicine, University of Paris Sud, Paris, France
    J Am Coll Cardiol 43:5S-12S. 2004
    ....
  72. doi request reprint Pulmonary hypertension in patients with neurofibromatosis type I
    David Montani
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Medicine (Baltimore) 90:201-11. 2011
    ..Further studies are needed to better understand the pathophysiology and the role, if any, of neurofibromin in NF1-associated PH...
  73. ncbi request reprint Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases
    Peter Dorfmuller
    Service d Anatomie et de Cytologie Pathologiques, Centre Hospitalier Universitaire Pitie Salpetriere, 47 83, Boulevard de l Hopital, F 75651 Paris Cedex 13, France
    Hum Pathol 38:893-902. 2007
    ....
  74. doi request reprint Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults
    Denis Chemla
    Paris Sud University EA4046, Medical Intensive Care Unit, Paris, France
    Chest 135:760-8. 2009
    ..Our study evaluated the accuracy and precision of various empirical formulas relating mPAP and sPAP in resting adults...
  75. doi request reprint [Pulmonary arterial hypertension and sickle cell disease]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, 94276 Kremlin Bicêtre, France
    Presse Med 42:338-46. 2013
    ..5m/s is used. At present, no specific treatments for pulmonary arterial hypertension is currently approved for the treatment of PAH associated with sickle cell disease due to lack of data in this specific population...
  76. ncbi request reprint Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Marc Humbert
    Center for Pulmonary Vascular Diseases, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Nat Clin Pract Rheumatol 1:93-101. 2005
    ..This article reviews PAH associated with systemic rheumatic diseases and describes the role of ERAs in this setting...
  77. ncbi request reprint Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension
    Vincent Castelain
    Department of Pulmonary Medicine UPRES 2705, Antoine Béclère Teaching Hospital, Clamart, France
    Am J Respir Crit Care Med 165:338-40. 2002
    ..1 mm Hg/L/min/m(2) (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise...
  78. ncbi request reprint Severe pulmonary arterial hypertension in type 1 glycogen storage disease
    Marc Humbert
    Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur J Pediatr 161:S93-6. 2002
    ....
  79. ncbi request reprint Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study
    Florence Parent
    Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Thromb Res 120:195-200. 2007
    ..However, their role as an exclusionary first-line test is still uncertain, mainly because accuracy of the test varies according to the assay and the studied population...
  80. ncbi request reprint CX(3)C chemokine fractalkine in pulmonary arterial hypertension
    Karl Balabanian
    INSERM U131, UPRES EA2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Institut Paris Sud sur les Cytokines, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 165:1419-25. 2002
    ..Fractalkine mRNA and protein product are expressed in pulmonary artery endothelial cells. We conclude that inflammatory mechanisms involving chemokine fractalkine and its receptor CX(3)CR1 may have a role in the natural history of PAH...
  81. doi request reprint Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
    S Provencher
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 32:393-8. 2008
    ..Improvement in exercise tolerance with chronic therapy is independently related to improvement in pulmonary haemodynamics measured in exercise but not in resting conditions...
  82. doi request reprint Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
    N Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Lancet 371:2093-100. 2008
    ..This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan in patients with WHO FC II pulmonary arterial hypertension...
  83. doi request reprint Pulmonary arterial hypertension masquerading as severe refractory asthma
    L Achouh
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 32:513-6. 2008
    ..The present observations add dilatation of the central pulmonary arteries with compression of the mainstem bronchi to the list of masqueraders of asthma in patients with pulmonary arterial hypertension...
  84. ncbi request reprint [Surgical treatment of post-embolism pulmonary hypertension]
    P Dartevelle
    département de chirurgie thoracique vasculaire et transplantation cardio pulmonaire, Hopital Marie Lannelongue, Universite Paris Sud, 133, avenue de la resistance, 92350 Le Plessis Robinson
    Rev Pneumol Clin 60:124-34. 2004
    ....
  85. ncbi request reprint Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension
    V Castelain
    Service de Pneumologie, , , Assistance Publique-H pitaux de Paris, Clamart, France
    J Am Coll Cardiol 37:1085-92. 2001
    ....
  86. ncbi request reprint [Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]
    O Sitbon
    Centre de référence national sur l HTAP, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Hopital Antoine Beclere, AP HP, Clamart
    Presse Med 34:1456-64. 2005
    ..The Pulmonary Vascular Diseases working group of the French Society of Pulmonary Medicine has developed guidelines for the best practices in use of these drugs...
  87. ncbi request reprint [Pulmonary arterial hypertension]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique, Hopitaux de Paris, Clamart, France
    Rev Mal Respir 22:651-66. 2005
    ..Pulmonary arterial hypertension (PAH) is a rare condition characterised by progressively elevated pulmonary arterial resistance leading to right heart failure...
  88. pmc Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Thorax 60:1025-30. 2005
    ....
  89. ncbi request reprint Survival with first-line bosentan in patients with primary pulmonary hypertension
    V V McLaughlin
    University of Michigan, 1500 East Medical Center Drive, Women s Hospital, Room L3119, Ann Arbor, MI, USA
    Eur Respir J 25:244-9. 2005
    ..First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension...
  90. ncbi request reprint [Treatments for pulmonary arterial hypertension]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Rev Med Interne 25:720-31. 2004
    ..We here present the different therapeutic alternatives available in the PAH and propose an algorithm for treatment of these patients...
  91. ncbi request reprint Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
    M Humbert
    Hopital Antoine Beclere, Assistance Publique, Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140, Clamart, France
    Eur Respir J 24:353-9. 2004
    ..Several cases of early and late major complications were reported. Additional information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension...
  92. ncbi request reprint Novel therapeutic perspectives in pulmonary arterial hypertension
    M Humbert
    Eur Respir J 22:193-4. 2003
  93. ncbi request reprint [Pulmonary artery hypertension associated with connective tissue diseases]
    O Sanchez
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart
    Presse Med 32:789-99. 2003
    ..In our centre of pulmonary vascular diseases, connective tissue diseases represent the third cause of PH...
  94. ncbi request reprint [Chronic pulmonary heart disease: therapeutic indications]
    R Azarian
    , , Clamart
    Arch Mal Coeur Vaiss 88:1799-805. 1995
    ..Of all the causes of pulmonary hypertension, chronic thromboembolic cor pulmonary should be systematically looked for because curative surgical treatment is possible in some cases...
  95. ncbi request reprint [Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France]
    D Lewis
    NERA Londres, 15 Stratford Place, Londres WIN 9AF, Royaume-Uni
    Presse Med 30:1539-48. 2001
    ..CONCLUSION: Tinzaparin reduced health care costs for pulmonary embolism due to easier administration, less complex laboratory tests, and personnel time savings. The robustness of the results was confirmed by the sensitivity analysis...
  96. ncbi request reprint Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia
    R C Trembath
    Department of Medicine, University of Leicester, United Kingdom
    N Engl J Med 345:325-34. 2001
    ..Because patients with hereditary hemorrhagic telangiectasia may have lung disease that is indistinguishable from primary pulmonary hypertension, we investigated the genetic basis of lung disease in these patients...
  97. ncbi request reprint Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
    S Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud IX, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 27:114-20. 2006
    ..The lack of chronotropic response may reflect the loss in normal physiological reserve in more unwell patients...
  98. ncbi request reprint The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
    R J Hughes
    Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridgeshire, CB3 8RE, UK
    Eur Respir J 28:138-43. 2006
    ....
  99. ncbi request reprint [Postembolic pulmonary hypertension]
    X Jais
    Centre de Référence de l Hypertension Artérielle Pulmonaire, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    Rev Mal Respir 24:497-508. 2007
    ..The consequence is an increase in pulmonary vascular resistance resulting in pulmonary hypertension (PH) and progressive right heart failure...
  100. ncbi request reprint Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    R J Barst
    Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
    Eur Respir J 28:1195-203. 2006
    ..In contrast, predicted survival was 69-38% over 1-4 yrs. The safety profile for long-term subcutaneous treprostinil was consistent with previous short-term trials with no unexpected adverse events...
  101. ncbi request reprint [Genetics of pulmonary arterial hypertension: recent data and practical applications]
    B Sztrymf
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Rev Mal Respir 22:796-805. 2005
    ..Beside idiopathic PAHT and that associated with other conditions, a familial form has been identified...